Genelux: Funding, Investors & Team (Oct 2026)
Genelux Corporation, a privately-owned biopharmaceutical company, has created a unique technology platform based on oncolytic viruses, along with a diverse range of products aimed at cancer detection and treatment. Their leading product candidate, GL-ONC1, is an attenuated vaccinia virus that has shown promising results in shrinking solid tumors in animals while leaving healthy tissues unharmed. GL-ONC1 includes a Green Fluorescent Protein for precise tumor imaging, aiding in cancer diagnosis and staging. The product is currently being tested in Phase I/II clinical trials in the US and Europe, with plans for additional trials in the near future. Early results show that GL-ONC1 is well-tolerated with minimal side effects and is demonstrating potential anti-tumor effects.
Genelux has raised $71.0M across 3 funding rounds on record, the most recent an undisclosed round of $10.5M announced in Mar 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Genelux Company Profile and Key Stats
Latest funding round on record: Mar 2025.
Genelux Funding Rounds
Genelux raised $33.0M in an undisclosed round announced in May 2023.
1 years later, an undisclosed round of $27.5M was announced in May 2024.
10 months later, an undisclosed round of $10.5M was announced in Mar 2025.
Genelux Founders and Leadership Team
No contact details are on record for this team yet.
Genelux Funding Compared to Other Biotechnology Startups
Genelux's latest round of $10.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Genelux in Biotechnology and Westlake Village
Companies Similar to Genelux
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Genelux Funding FAQs
What does Genelux do?
Genelux Corporation, a privately-owned biopharmaceutical company, has created a unique technology platform based on oncolytic viruses, along with a diverse range of products aimed at cancer detection and treatment. Their leading product candidate, GL-ONC1, is an attenuated vaccinia virus that has shown promising results in shrinking solid tumors in animals while leaving healthy tissues unharmed. GL-ONC1 includes a Green Fluorescent Protein for precise tumor imaging, aiding in cancer diagnosis and staging. The product is currently being tested in Phase I/II clinical trials in the US and Europe, with plans for additional trials in the near future. Early results show that GL-ONC1 is well-tolerated with minimal side effects and is demonstrating potential anti-tumor effects.
How much funding has Genelux raised?
Genelux has raised $71.0M across 3 rounds on record. The most recent is an undisclosed round of $10.5M announced in Mar 2025.
When did Genelux last raise funding?
Genelux's most recent funding round on record is an undisclosed round of $10.5M, announced in Mar 2025.
Who founded Genelux?
FundedIQ lists Aladar Szalay (Founder), Thomas Zindrick (Founder) at Genelux.
Where is Genelux headquartered?
Genelux is based in Westlake Village, California, United States.
How many employees does Genelux have?
Genelux is in the 11-50 employee band.
How does Genelux's funding compare to other Biotechnology startups?
Genelux's latest round of $10.5M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Genelux Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Genelux is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.